Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease

Jacob Tveiten Bjerrum*, Casper Steenholdt, Mark Ainsworth, Ole Haagen Nielsen, Michelle A.C. Reed, Karen Atkins, Ulrich Leonhard Günther, Fuhua Hao, Yulan Wang

*Corresponding author for this work
10 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease'. Together they form a unique fingerprint.

Biochemistry, Genetics and Molecular Biology